Kamada Completes Successful IMOH GMP Audit

Kamada Ltd. has completed a successful GMP audit of its manufacturing facility in Beit Kama, Israel by the Israeli Ministry of Health (IMOH). The audit was performed as part of a routine evaluation of the company’s manufacturing process for its plasma-derived protein therapeutics. The audit concludes that Kamada complies with GMP requirements for the manufacture of medicinal products, the importation of medicinal products and the manufacture of active substances using biological processes.
 
“Kamada takes great pride in maintaining the highest quality manufacturing processes as it is a core competency of the Company and a cornerstone of our commercial success. This positive audit underscores the viability, quality and high standards Kamada upholds in the manufacture of our plasma-derived therapeutic proteins both for commercial use and for products under development in compliance with international standards,” said David Tsur, chief executive officer of Kamada.